Cancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th

RUTHERFORD, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will release its financial results for the second quarter 2017, on Monday, August 14, 2017. The Company will also hold an earnings call at 5:00 PM Eastern on Monday, August 14, 2017 to discuss the financial results and provide company updates.

Conference Call & Webcast
Monday, August 14, 5:00 PM Eastern Time
Domestic:  877-440-5804
International:  719-457-1506
Conference ID: 2840579
Replays – Available through August 28, 2017
Domestic:  844-512-2921
International:  412-317-6671
Conference ID:  2840579


Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:
Twitter: @Cancer_Genetics

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “esti   mates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations Contact:
Richard Moyer
Cameron Associates
535 Fifth Ave., New York, NY 10017
Tel: 212-554-5466


You May Also Like


美國丹佛, Aug. 22, 2018 (GLOBE NEWSWIRE) -- 活動內容:國際肺癌研究協會(IASLC)定於2018年9月23日至26日在加拿大多倫多舉辦IASLC第19屆世界肺癌大會(WCLC)。世界肺癌大會是全球規模最大並專門探討肺癌及其他胸部惡性腫瘤的會議,預計將匯聚來自世界各地逾7,000名研究人員、醫生、專家、患者、宣導者和從業人員。 世界肺癌大會的學術交流活動將會包括由全球業界領袖組成的講者陣容。演講內容重點關注尖端科研成果,包括靶向療法和免疫療法領域最新的重大突破,篩查、早期檢測和癌症分期技術的進展,癌症預防及戒煙相關工作情況,患者倡議活動等。跨學科跨國界合作是該大會的一大特色。世界肺癌大會的學術交流活動可供網上回顧。 時間地點:日期:2018年9月23日至26日 場館:Metro Toronto Convention Centre ...